European Biosimilars Can Benefit From Sharing Experiences
Policy Solutions Discussed At Medicines For Europe Virtual Summit
Attendees to Medicines for Europe’s virtual summit on biosimilars heard how learning from experiences across Europe can allow individual countries to build a toolbox of policies to help create a sustainable biosimilars market.
You may also be interested in...
Panellists at a recent webinar hosted by Sandoz on “unlocking the potential of biosimilars” agreed that biologics are increasingly advancing to first-line treatments. However, industry and regulatory leaders cited lack of education as a significant barrier to biosimilars uptake. The experts also offered reasons for the reduced uptake in immunology biosimilars compared to oncology.
Medicines for Europe has made a series of recommendations to improve the contribution of generics, biosimilars and value-added medicines to the European Commission’s “Beating Cancer Plan.” The association has offered a checklist of key policies to “ensure equity and quality of cancer care is achieved.”
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.